SCHEMBL1632089

SCHEMBL1632089

CC(C)(C)NC1CC(=O)N(C(C)(C)C)C1=O

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23978582 0.78 ALDH1A1 (0.45) POLB
SCHEMBL19702964 0.73 CYP2C19 (0.40) POLB
SCHEMBL23132512 0.72
SCHEMBL18811909 0.71 POLB (0.33) POLB
SCHEMBL12219733 0.71 POLB (0.33) POLB
SCHEMBL20228114 0.69 MT-CO2 (0.33) POLB
SCHEMBL1753618 0.69 MT-CO2 (0.33) POLB
SCHEMBL19599183 0.69 CYP2C19 (0.38) POLB
SCHEMBL14275619 0.69 MAPT (0.36) POLB
SCHEMBL19599188 0.69 CYP2C19 (0.38) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364277-A1 E-SELECTIN TARGETING AGENTS GLYCOMIMETICS, INC. (US) 2023-11-16 US disclosed
US-20230364277-A1 E-SELECTIN TARGETING AGENTS GLYCOMIMETICS, INC. (US) 2023-11-16 US disclosed
US-20230167149-A1 CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS GLYCOMIMETICS, INC. (US) 2023-06-01 US disclosed
US-20230167149-A1 CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS GLYCOMIMETICS, INC. (US) 2023-06-01 US disclosed
US-20230167150-A1 CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS GLYCOMIMETICS, INC. (US) 2023-06-01 US disclosed
US-8779090-B2 Methods and compositions for the treatment of heart failure and other disorders IRONWOOD PHARMACEUTICALS, INC. (US) 2014-07-15 US disclosed
US-20120283411-A9 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-11-08 US disclosed
US-20120088902-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2012-04-12 US disclosed
US-20120040892-A9 Methods and Compositions for the Treatment of Heart Failure and Other Disorders WELLS FARGO BANK, NATIONAL ASSOCIATION 2012-02-16 US disclosed
US-20110306125-A1 Protein Expression Methods IRONWOOD PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed
US-20110021419-A1 Methods and Compositions for the Treatment of Heart Failure and Other Disorders Ironwood Pharmaceuticals Inc. 2011-01-27 US disclosed
US-20090305993-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2009-12-10 US disclosed
US-20090192083-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS IRONWOOD PHARMACEUTICALS, INC. 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021419-A1 Methods and Compositions for the Treatment of Heart Failure and Other Disorders GCGR, GCG, GIPR POLB 4577/4885
US-20230167150-A1 CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS SIGLEC7, SIGLEC9, CD47 POLB 4737/4885
US-20120040892-A9 Methods and Compositions for the Treatment of Heart Failure and Other Disorders GCGR, GCG, GIPR POLB 4577/4885
US-20120088902-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GRPR, GCGR, GIPR POLB 2079/4885
US-20120283411-A9 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GRPR, GCGR, GIPR POLB 2079/4885
US-20230167149-A1 CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS SIGLEC7, SIGLEC9, ASGR1 POLB 4637/4885
US-20230364277-A1 E-SELECTIN TARGETING AGENTS SELE, SELPLG, SELP POLB 4584/4885
US-20110306125-A1 Protein Expression Methods GUCY1B2, GUCY1A2, GUCY1B1 POLB 4475/4885
US-20090192083-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GRPR, GCGR, GIPR POLB 1772/4885
US-20090305993-A1 METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS GIPR, VIP, GCGR POLB 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.